“We have helped developed policies at the national level as far as parental leave for residents and fellows, helping to streamline a lot of that process with the American Board of Urology,” says Daniel Igel, MD.
Daniel Igel, MD, discusses his role as the South Central Section representative to the AUA residents and fellows committee. Dr. Igel is one of the chief urology residents at the University of Kansas Medical Center. Next year, he will be pursuing a fellowship in urologic oncology at the University of Texas MD Anderson Cancer Center.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.